НовостиBenzingaRBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $459 RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $459 Benzinga 2026.10.08 14:43 (GMT+0) Открыть на Benzinga Другие новости